drugset / Trial / NCT02881242
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Active not recruiting
14 enrolled
Jonsson Comprehensive Cancer Center
Novartis · collabProstate Cancer Foundation · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well trametinib works in treating patients with hormone-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2018-01-30
- Primary completion
- 2024-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trametinib | Small molecule | — | Oral |